Pitt Street Research | Stock research
Paradigm.png

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals is an ASX-listed drug development company. Paradigm’s flagship asset is Zilosul, an injectable form of pentosan polysulfate sodium (PPS). Zilosul is a non-opioid, anti-inflammatory drug that Paradigm is seeking to use to treat multiple indications, most particularly osteoarthritis. Zilosul is in Phase 3 for osteoarthritis having passed multiple Phase 2 trials. The drug has been Fast Tracked by the FDA and has the opportunity for expedited approval in Australia through TGA Provisional Approval.

Paradigm Biopharmaceuticals (ASX:PAR)

 

Paradigm Biopharmaceuticals is an ASX-listed drug development company. Paradigm’s flagship asset is Zilosul, an injectable form of pentosan polysulfate sodium (PPS). Zilosul is a non-opioid, anti-inflammatory drug that Paradigm is seeking to use to treat multiple indications, most particularly osteoarthritis. Zilosul is in Phase 3 for osteoarthritis having passed multiple Phase 2 trials. The drug has been Fast Tracked by the FDA and has the opportunity for expedited approval in Australia through TGA Provisional Approval.